Alvotech Holdings S.A. Business Combination with Oaktree Acquisition Corp. II (Nasdaq ALVO)

Rallybio Corporation to Acquire Avenzo Therapeutics in $215M Financing Deal

June 2, 2026

Biotechnology

Rallybio Corporation entered into a definitive merger agreement to acquire Avenzo Therapeutics, with the combined company expected to operate as Avenzo Therapeutics, Inc. and trade on Nasdaq under the ticker symbol AVZO. The transaction includes a concurrent, oversubscribed $215 million private placement with participation from healthcare institutional investors and mutual funds, and is expected to close in Q4 2026 subject to customary conditions.

EQT X to Acquire Adalvo (B2B Generic Drug Dossiers)

July 18, 2025

Healthcare Services

EQT X (EQT) has agreed to acquire a majority stake in Adalvo, an asset-light B2B dossier developer that produces market-approval-ready generic drug dossiers for pharmaceutical companies. Existing shareholders, including Aztiq (holding company of Chairman Róbert Wessman), will reinvest part of their holdings and retain minority ownership. The deal is subject to customary approvals and is expected to close in H2 2025.

Avant Technologies Proposes Acquisition of Ainnova Tech to Consolidate Vision AI JV

May 13, 2025

Healthcare Services

Avant Technologies has entered formal negotiations to acquire its joint-venture partner Ainnova Tech (operating through Ai-nova Acquisition Corp.), aiming to merge the businesses ahead of an FDA pre-submission meeting. The deal is intended to streamline regulatory coordination, speed clinical development and support U.S. market entry for the Vision AI clinical screening platform currently piloted across Latin America.

Atlantic Coastal Acquisition Corp. II Completes Business Combination with Abpro Corporation

November 13, 2024

Biotechnology

Abpro Corporation and Atlantic Coastal Acquisition Corp. II completed their business combination and the combined company will operate as Abpro Holdings, Inc., with Abpro Corporation as a wholly owned subsidiary. The company is expected to begin trading on Nasdaq under the ticker ABP (and ABPWW for warrants); South Korea's Celltrion participated in a $5.0 million PIPE and appointed Soo Young Lee to Abpro's board.

EQT (via Otello BidCo AB) Acquires OX2 AB

October 8, 2024

Energy

EQT Infrastructure VI, through acquisition vehicle Otello BidCo AB, completed a recommended public offer to acquire 100% of OX2 AB at SEK 60 per share and now controls 98.81% of the company; OX2 has applied for delisting from Nasdaq Stockholm. EQT says it will support OX2's evolution from a pure developer to an integrated renewables developer and asset owner and provide additional investment to grow the company's pipeline across onshore/offshore wind, solar and storage.

PureTech Acquires Remaining Interest in Alivio Therapeutics

June 16, 2021

Biotechnology

PureTech Health plc acquired the remaining 22% of shares in its Founded Entity, Alivio Therapeutics, integrating Alivio's anti-inflammatory therapeutic programs — including LYT-500 and LYT-503/IMB-150 — into PureTech's Wholly Owned Pipeline. The transaction consolidates PureTech's ownership of Alivio and is expected to fund and advance the programs through PureTech's immunology and related technology capabilities.